Sage changes primary endpoint in key study months after analysts fret about depression drug's durability

Max Gelman

Senior Editor

In its quest to deliver a new drug to treat major depressive disorder, Sage Therapeutics recently updated its Phase III study with a change analysts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage changes primary endpoint in key study months after analysts fret about depression drug's durability

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

How AI can address ongoing challenges in the life sciences industry

Sage changes pri­ma­ry end­point in key study months af­ter an­a­lysts fret about de­pres­sion drug's dura­bil­i­ty

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sage changes primary endpoint in key study months after analysts fret about depression drug's durability